BioTrends RESEARCH GROUP
A Decision Resources Group Company

REPORT OVERVIEW

TreatmentTrends®: Chronic Kidney Disease Stages 1-5ND (US)

TreatmentTrends® are syndicated report series that provide longitudinal information on market dynamics. They provide insight into practice patterns, attitudes and perceptions, and current and projected use of various products. This BioTrends report series provide key details on how U.S. patients in all pre-dialysis stages of chronic kidney disease (CKD) are managed: early disease (stage 1 and 2), mid-stage disease (stage 3) and late-stage disease (stage 4 and 5 not on dialysis). Two waves of the study published in 2012 in order to observe changing trends.

SAMPLE FRAME AND METHODOLOGY

45-60 minute online quantitative survey with several open-ended questions for qualitative feedback completed by 250 US physicians (100 nephrologists, 100 primary care physicians, and 50 endocrinologists)

Screening Criteria:

- In practice between 2 and 30 years
- Over 50% of time spent on patient care
- For nephrologists: minimum of 100 CKD-ND patients under management, with at least 50 patients in each stage of CKD
- For endocrinologists and PCPs: have treated at least 200 total patients per month and a minimum of 50 CKD-ND patients under management

RELATED REPORTS

TreatmentTrends®: US Nephrology

ChartTrends®: Bone and Mineral Metabolism in CKD-ND (US)

ChartTrends®: Renal Anemia in CKD-ND (US)

Pharmacor CKD

PROJECT OBJECTIVES

- Understand the CKD patient population
  - How many patients in each CKD Stage are the physician specialties treating?
  - What referral patterns exist and what are the specialties' perceptions of these referral patterns?
- Understand the diagnosis and standard of care for patients with CKD and how therapy decisions differ based on early, mid or late disease
  - What are the current screening protocols (including labs) and diagnosis patterns?
  - What is the frequency of treatment for related diseases by physician specialty: diabetes, congestive heart failure, hypertension, cholesterolemia, obesity, anemia, bone and mineral metabolism disruptions, hyperkalemia, hypernatremia?
  - What are preferred first-line agents and drug combinations?
  - What triggers treatment?
- Understand the satisfaction with current treatment, challenges with treatment, and the unmet needs in the management of CKD
  - Specifically, how might developmental agents (e.g. CTP-499, LY2382770, etc.) be used in these patient populations?

DELIVERABLES

- Final report is in PowerPoint format
- Custom ad-hoc analysis available upon request with purchase of the report
- Access to analyst team for presentation or to address questions

REPORT DATES

Field date	Publication date
April 10, 2013	June 28, 2013

For more information, or the full report, please contact Alexander Cline, Account Manager at 781-993-2662 or acline@dresources.com

Report ID: TRTRNE0113
Updated February 28, 2013

TREATMENTTRENDS®: CHRONIC KIDNEY DISEASE STAGES 1-5ND (US)

TABLE OF CONTENTS

- **Background, Methods and Objectives** 4
  - Disease background: What is CKD?
  - Secondary data including CKD prevalence, causes of CKD, pre-ESRD care (e.g., USRDS, NHANES, etc.)
  - Estimated CKD patient costs
  - CKD and cardiovascular disease
  - Hospitalization and mortality rates in CKD
  - Key CKD market news
  - Methodology
  - Significance testing and report abbreviations
  - Objectives and products and companies profiled

- **Executive Summary** 22
  - Disease background, diagnosis, nephrology referral and symptoms
  - Treatment with drug classes by stage of disease
  - Products in development (familiarity, interest after review of short product profile, percentage of patients likely candidates by stage)

- **Physician Demographics**..... 26
  - Practice demographics: Wave 3
  - Patient load by nephrologists, endocrinologists and PCPs
  - Current unmet need in nephrology diseases
  - Recent changes in the management/treatment of CKD
  - CKD disease progression

- **Current Diagnosis Patterns in CKD** 34
  - Diagnosis of CKD patients by physicians
  - When are CKD patients diagnosed?
  - Perceived changes to the CKD diagnosis rate
  - Laboratory testing for diagnosis of CKD: By specialty
  - Variability of CKD diagnostics and awareness of new biomarkers
  - Symptoms of CKD patients
  - Lab values ordered upon diagnosis: by physician type by stage
  - Importance of various labs
  - Target lab values for HBA1C, phosphorous, calcium, PTH and blood pressure
  - Laboratories from which labs are ordered
  - Satisfaction with labs
  - Important qualities in a lab

- **Referral Patterns in CKD** 53
  - Referrals of CKD patients by PCPs
  - Referrals of CKD patients by endocrinologists
  - Referrals to nephrologists
  - Referrals to CKD patients to nephrologists: Nephrologist perspective
  - Reasons for referral by physician type
  - Relationship post-referral
  - Co-management of CKD-ND patients
  - Referrals to cardiologists: Nephrologist perspective

TABLE OF CONTENTS (CONT'D)

- **Current Treatment Patterns in CKD** ……. **66**
  - Comorbidities of CKD patients
  - Control of hypertensions in CKD-ND
  - Frequency of patient visits by nephrologists, endocrinologists and PCPs
  - Treatment by drug classes by stage (12 classes)
  - Reasons for nontreatment
  - Available methods for attempting to slow CKD progression
  - CKD attribute importance
  - ACE inhibitors by molecule: treatment by physician type
  - ARBs by molecule: treatment by physician type
  - Phosphate binders by brand by stage
  - ESAs by brand by stage
  - PTH modifiers by brand by stage
  - Interchangeability of CKD therapies
  - Lifestyle interventions
  - Compliance of CKD patients with treatment (10 classes and lifestyle intervention)
  - CKD disease progression
  - Impact on slowing the progression of CKD
  - CKD treatment attribute importance
- **Future Treatment for CKD** …….. **104**
  - Key new therapies in development
  - Awareness of CKD products in development
  - Discontinuation and Impact of the Phase III Bardoxolone Trial
  - Mechanism of action with most promise for new CKD treatment
  - Familiarity, interest and percentage of patients likely candidates with CKD agents in development (Lilly's LY2382770, Pfizer's PF 04634817, Pfizer's PF 00487791, Fibrogen's FG3019, Mitsubishi Tanabe's MP-146/ AST-120, Concert Pharmaceuticals' CTP-499, and Abbvie's atrasentan)
  - Desired clinical endpoint specifically for diabetic nephropathy (controlling proteinuria vs. slowing GFR)
  - Timing of intervention with a new CKD agent
  - Trigger for prescribing new medication
  - Sources for obtaining information about CKD-ND
  - Conference attendance
  - Statement agreement
- **Appendix** …… **127**